Here are the 10-K annual reports from Interpace Biosciences New (IDXG) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow IDXG and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full IDXG filings page.
Interpace Biosciences, Inc. filed Amendment No. 1 to its Annual Report for the year ended December 31, 2025 to add Part III information on directors, executive compensation, security ownership, related-party matters and auditor fees that was originally expected to come from a proxy statement.
The filing details a five-member classified board, committee structures and independence determinations, and compensation for named executives. In 2025, CEO Thomas W. Burnell earned total compensation of $708,192, while CFO and COO Christopher McCarthy earned $468,265. Non-employee directors each received cash fees of up to $50,000.
The amendment also shows ownership concentration, with Ampersand 2018 Limited Partnership holding 13,861,386 shares (50.0%) and 1315 Capital II, L.P. holding 9,405,941 shares (34.0%) as of April 15, 2026, when 27,700,904 common shares were outstanding. Audit fees paid to EisnerAmper LLP were $320,250 for 2025. No new financial statements are included.
Interpace Biosciences, Inc. reported 2025 revenue of $38.7 million, down from $46.9 million in 2024. The decline was primarily driven by CMS ending reimbursement coverage for PancraGEN on April 24, 2025; Interpace stopped accepting specimens for the test after May 2, 2025. The company is concentrating on its thyroid tests, ThyGeNEXT and ThyraMIR v2. Gross profit was $24.1 million versus $29.9 million, and operating income was $4.1 million versus $8.1 million.
Net income was $24.6 million, compared with $6.7 million, largely reflecting a $21.2 million income tax benefit from a partial release of the valuation allowance. Adjusted EBITDA, a non-GAAP measure, was $5.434 million versus $8.699 million. Operating cash flow was $5.8 million compared with $4.6 million. Interpace paid the BroadOak term loan in full in November 2025 and reported $2.5 million of cash and cash equivalents at year-end.